OraSure Technologies (OSUR) to Release Quarterly Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is set to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect OraSure Technologies to post earnings of $0.04 per share for the quarter. OraSure Technologies has set its Q1 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The business had revenue of $75.88 million for the quarter, compared to analyst estimates of $74.13 million. During the same quarter in the previous year, the firm posted $0.21 earnings per share. OraSure Technologies’s revenue was down 38.3% compared to the same quarter last year. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Price Performance

Shares of OraSure Technologies stock opened at $5.49 on Monday. The company has a market cap of $420.04 million, a PE ratio of 7.63 and a beta of 0.23. The firm has a fifty day moving average price of $6.18 and a two-hundred day moving average price of $6.81. OraSure Technologies has a fifty-two week low of $4.38 and a fifty-two week high of $8.45.

Analysts Set New Price Targets

OSUR has been the topic of a number of recent research reports. Evercore ISI decreased their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. StockNews.com raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.